Skip to main content

Table 1 Clinical data of MS patients and non-neurological controls

From: Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis

Case Age (years) MS type Sex Post-mortem delay (h:min) Disease duration (years) Lesion stages
MS 1 73 ND m 6:45 26 CIA
MS 2 63 PP m 7:05 25 CA
MS 3 56 SP m 8:00 27 CIA
MS 4 66 ND m 7:45 ND A
MS 5 41 PP m 7:20 14 A, CA
MS 6 49 SP m 8:00 25 CIA
MS 7 66 PP m 7:30 26 2*CA
MS 8 61 SP m 9:15 30 3*CA, CIA
MS 9 44 PP m 12:00 13 CA
MS 10 44 SP m 10:15 22 CA
MS 11 54 PP m 8:15 15 3*A
MS 12 45 AMS m ND 1 week 3*A, CA, CIA
MS 13 35 AMS m ND 6 weeks 5*A, 2*CIA
MS 14 40 RR f ND 10 A
MS 15 34 AMS f ND 0,3 A
MS 16 78 AMS m ND 0,2 A, CA
MS 17 41 SP m ND 10,6 A
MS 18 46 SP f ND 37 CA, CIA
MS 19 51 AMS f ND 0,5 A, 3*CA
Ctrl 1 66 NA f 7:00 NA NA
Ctrl 2 71 NA m 8:55 NA NA
Ctrl 3 58 NA m 5:15 NA NA
Ctrl 4 62 NA m 7:20 NA NA
Ctrl 5 78 NA m 17:40 NA NA
Ctrl 6 51 NA f 5:36 NA NA
Ctrl 7 70 NA m ND NA NA
Ctrl 8 46 NA m ND NA NA
Ctrl 9 37 NA m ND NA NA
Ctrl 10 39 NA f ND NA NA
  1. SP = secondary progressive MS; PP = primary progressive MS; AMS = Acute MS; ND = not determined; NA = non applicable; m = male; f = female; A = active lesion; CA = chronic active lesion; CIA = chronic inactive lesion.